EJF Acquisition Corp. (EJFA) Shareholders Approve Pagaya Deal
by Marlena Haddad on 2022-06-17 at 5:03pm

EJF Acquisition Corp. (NASDAQ:EJFA) announced this afternoon that its shareholders have voted to approve its combination with Israeli fintech firm Pagaya in a special meeting held earlier today.

Although today’s press release was short on details and did not disclose redemption numbers, EJFA traded slightly above its trust value of $10 throughout its redemption deadline June 15. However, the SPAC closed today at just $5.63.

Earlier this year, EJF upsized the PIPE for its combination with Pagaya from $200 million to $350 million. The upsized PIPE was led by a group of long-term investors including Tiger Global, Whale Rock, Singapore’s sovereign wealth fund, the Healthcare of Ontario Pension Plan, and G Squared. EJF originally brought $288 million into the transaction from its trust, which it supplemented with a $200 million PIPE at deal announcement. The funding from the original $200 million PIPE already covered the deal’s $200 million minimum cash closing condition.

The parties now expect to close the deal on June 22, 2022 and following the closing, the publicly listed company will be named Pagaya Technologies Ltd. The combined company’s shares and public warrants are expected to begin trading on the Nasdaq stock market under the symbols “PGY” and “PGYWW”, respectively.

EJF initially announced the $8.5 billion combination with Pagaya on September 15. Tel Aviv-based Pagaya provides an AI-powered platform matching customers with third-party credit products both applying for loans and at the point-of-sale (POS).


ADVISORS

  • UBS Investment Bank is serving as lead financial and capital markets advisor to EJFA.
  • Barclays is also serving as financial and capital markets advisor to EJFA.
  • Simpson Thacher & Bartlett LLP is serving as legal counsel to EJFA in connection with the transaction.
  • Duff & Phelps, A Kroll Business, rendered a fairness opinion to EJFA’s Board of Directors.
  • J.P. Morgan Securities LLC is serving as exclusive financial advisor to Pagaya.
  • Skadden, Arps, Slate, Meagher & Flom LLP and Goldfarb Seligman & Co. are serving as legal counsel to Pagaya.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved